-
2024-514912-28-00
10
2025-10-22
Patients with hepatocellular carcinoma with high tumor burden.
-
2024-520413-53-00
5
2025-10-21
Spinocerebellar ataxia
-
2023-510558-18-00
4
2025-10-13
locally advanced head and neck squamous cell carcinoma
-
2023-508056-19-00
5
2025-10-02
HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P
-
2024-511871-13-00
6
2025-10-02
Postmenopausal osteoporosis
-
2024-519445-29-00
1
2025-10-02
Solid Tumors
-
2024-516410-38-00
4
2025-10-01
Pyruvate dehydrogenase deficiency
-
2024-515199-10-01
4
2025-09-29
Retinitis Pigmentosa
-
2024-518916-38-00
4
2025-09-29
knee synovitis and osteoarthritis
-
2024-517016-30-00
4
2025-09-26
Crohn’s disease
-
2024-520210-21-00
5
2025-09-19
Crohn’s Disease
-
2024-513613-12-00
9
2025-09-18
Part A: Healthy volunteers (Part A is not applicable to the EU; for in
-
2024-511663-28-00
6
2025-09-11
Asymptomatic Child-Pugh A5 to B8 cirrhosis
-
2024-516982-35-00
5
2025-09-11
Ovarian Cancer
-
2024-515241-41-00
4
2025-09-10
Ulcerative Colitis
-
2024-518325-15-00
5
2025-09-08
Gastroenteropancreatic neuroendocrine tumor (GEP-NET)
-
2024-510943-76-00
5
2025-09-03
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
-
2024-514030-20-00
4
2025-08-29
colorectal cancer
-
2024-518154-16-00
5
2025-08-27
non-small cell lung cancer
-
2024-514954-63-00
9
2025-08-20
RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS
-
2024-515875-36-00
4
2025-08-18
Advanced biliary tract cancer (BTC)
-
2024-515431-30-00
5
2025-08-14
Men treated with proctectomy for rectal cancer
-
2023-509630-19-00
5
2025-07-31
Esophageal Squamous Cell Carcinoma (ESCC)
-
2024-515349-41-00
4
2025-07-29
Metastatic Breast Cancer HR+, HER2-